E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10038997 |
E.1.2 | Term | Retroviral infections |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1) To verify the persistent control of the virus replication at 48 weeks after the simplification to tenofovir + emtricitabina + raltegravir or to lamivudine+abacavir+raltegravir in patients with optimal virological suppression without any virological failure to previous combined antiretroviral therapies |
|
E.2.2 | Secondary objectives of the trial |
 Time to virological failure (two consecutive HIV-RNA levels > 50 copies/mL or a single value >1000 copies/mL) at survival analysis  Proportion of patients with viral load lower than 50 copies/mL at 48 weeks at the intention to treat analysis  Evolution of CD4 cell count during the 48 weeks of study  Evolution of adherence and quality of life during the 48 weeks of study  Evolution of raltegravir plasma concentrations during the 48 weeks of study  Evolution of metabolic parameters during the 48 weeks of study  Change of the results of neurocognitive tests at 48 weeks of study  Change of bone density and of adipose tissue by DEXA analysis at 48 weeks of study |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients treated with a combined antiretroviral therapy from at least 1 year Aged 18 years or older With one or more of the following conditions: &#61692; Grade 3 or 4 Dyslipidemia &#61692; Any Hyperglicemia &#61692; Lipodystrophy (patient�s self report, confirmed by physician�s physical examination) &#61692; Moderate/severe cardiovascular risk, defined as a calcium score higher than 40 or a Framingham score higher than 10 (estimated 10 years cardiovascular risk: 10%) &#61692; Diarrhea (at least 3 emissions of loose stool every day for at least 3 days every week) With at least two HIV-RNA levels <50 copies/mL on two consecutive determinations at least 3 months apart With CD4 cell count >200 cells/ &#956;L for at least 6 months and absence of any opportunistic infection or AIDS-related disease during the last year before screening. Who gave informed consent to the participation to the study |
|
E.4 | Principal exclusion criteria |
Pregnancy or breast feeding, desire of pregnancy in the short term Previous virological failure (two consecutive HIV-RNA levels > 50 copies/mL or a single value >1000 copies/mL) to antiretroviral therapy and/or previous exposure to mono- or dual therapies with reverse transcriptase nucleoside analogues except for patients with subsequent genotypic resistance tests showing no resistance mutations to any of the study drugs. Previous exposure to inhibitors of HIV-1 integrase Previous major toxicity to any of the study drugs Spontaneous treatment interruptions in disagreement with the treating physician in the last year or loss to follow-up for at least 6 months, at least once in the last two years Current alcohol or drug abuse or any other condition which, in the judgment of the treating physician, may impair the patient�s adherence to the new drug regimen and/or to the protocol�s procedures Patients with grade 3 or 4 laboratory abnormalities at screening (except for lipid and glucose levels) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
proportion of patients with virological failure (two consecutive HIV-RNA levels > 50 copies/mL or a single value >1000 copies/mL) within 48 weeks at intention-to.treat analysis |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |